🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

964 results for “Advanced” Clear

  1. -, DOCETAXEL , JDQ443

    Novartis Ophthalmics Europe

    Advanced non-small cell lung cancer harboring the KRAS G12C mutation

    phase 3 small molecule active

    1 trial

  2. -, IRINOTECAN , PARACETAMOL , -, -, PACLITAXEL , TRIFLURIDINE, COMBINATIONS, MK-2870, DOCETAXEL

    Merck Sharp and Dohme

    advanced or metastatic gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma

    phase 3 small molecule active

    1 trial

  3. 2 cycles induction chemotherapy

    First Tracks Biotherapeutics

    Locally Advanced Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  4. 5-FU medac 50 mg/ml, Injektionslösung, Tecentriq 1 200 mg concentrate for solution for infusion, Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion, Leucovorin 10 mg/ml Lösung zur Injektion/ Infusion, Oxaliplatin medac 5 mg/ml concentrate for solution for infusion

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    locally advanced resectable adenocarcinoma of the oesophagogastric junction or the stomach

    phase 3 small molecule active

    1 trial

  5. 64Cu(II)Cl2 solution for injection

    A.C.O.M. - Advanced Center Oncology

    Cancer on the prostatic bed

    phase 3 small molecule active

    1 trial

  6. 64Cu(II)Cl2 solution for injection, Fluorocolina (18F) Curium Italy 225 MBq/mL soluzione iniettabile

    A.C.O.M. - Advanced Center Oncology

    Prostate cancer at risk of developing metastatic lesions

    phase 3 small molecule active

    1 trial

  7. A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (BFAST: Blood First Assay Screening Trial)

    Roche Registration Limited

    Advanced or metastatic Non-small cell lung cancer (NSCLC)

    phase 3 other active

    1 trial

  8. A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients with previously treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer

    Roche Registration Limited

    KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

    phase 3 other active

    1 trial

  9. A study to compare pharmacokinetics, efficacy, safety, and immunogenicity of MB12 (proposed pembrolizumab biosimilar) to Keytruda® in non-small cell lung cancer

    Mabxience Research SL

    advanced/metastatic non-squamous non-small cell lung cancer (NSCLC)

    phase 3 other active

    1 trial

  10. AG-120/S95031 250mg film-coated tablet, Ivosidenib-matched Placebo Tablets

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 or 2 systemic treatment regimens

    phase 3 small molecule active

    1 trial

  11. ALPELISIB, ALPELISIB, ALPELISIB

    Cancer Prevention Pharma (Ireland) Limited

    PIK3CA mutated HER2+ advanced or relapsed breast cancer (BC) previously treated with trastuzumab

    phase 3 small molecule active

    1 trial

  12. ALPELISIB, FULVESTRANT, ALPELISIB, Placebo to BYL719 50 mg film-coated tablet Light pink Placebo to BYL719 200 mg film-coated tablet Light red

    Novartis Ophthalmics Europe

    Hormone receptor positive, HER2-negative advanced breast cancer

    phase 3 small molecule active

    1 trial

  13. ANHYDROUS DOCETAXEL, FLUOROURACIL, FLUOROURACIL, OXALIPLATIN, CALCIUM LEVOFOLINATE

    CERO THERAPEUTICS HOLDINGS, INC.

    Locally advanced or metastatic oesogastric adenocarcinoma

    phase 3 small molecule active

    1 trial

  14. ASP8951, Sodium Chloride 0.9% Intravenous Infusion BP

    Astellas Pharma GmbH

    Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

    phase 3 small molecule active

    1 trial

  15. AVELUMAB, DOSTARLIMAB, ATEZOLIZUMAB, AVELUMAB, CEMIPLIMAB, DOSTARLIMAB, NIVOLUMAB, PEMBROLIZUMAB, NIVOLUMAB, DURVALUMAB, CEMIPLIMAB, ATEZOLIZUMAB, PEMBROLIZUMAB, DURVALUMAB

    Cancer Prevention Pharma (Ireland) Limited

    Only patients with oncologic locally advanced or metastatic tumour (lung cancer, renal cell cancer (except IMDC favorable-risk treated Tyrosine Kinase Inhibitor [TKI] / immunotherapy [IO] combination), head and neck cancer, urothelial carcinoma, triple negative breast cancer, Merkel cancer, melanoma, hepatocellular carcinoma, colorectal carcinoma with microsatellite instability [MSI], esophageal squamous cell carcinoma, endometrial carcinoma, or cervical cancer, gastric/gastro-esophageal junction/esophageal adenocarcinoma, basal cell carcinoma or squamous skin carcinoma) in partial or complete response (except for melanoma, only patients in partial response) after 6 months of standard IO treatment (monotherapy or previously in combination with other immunotherapy (ipilimumab) or chemotherapy or continuous combination with pemetrexed or bevacizumab or TKI).

    phase 3 small molecule active

    1 trial

  16. AZD8205, PACLITAXEL, DOXORUBICIN

    AstraZeneca AB

    B7-H4-Selected Advanced/Metastatic Endometrial Cancer.

    phase 3 small molecule active

    1 trial

  17. Abemaciclib, Lasofoxifene, Fulvestrant

    Pharma Mar S.A.

    Locally advanced or metastatic breast cancer

    phase 3 small molecule active

    1 trial

  18. Afinitor 10 mg tablets, Aromasin 25 mg coated tablets, Faslodex 250 mg solution for injection., Afinitor 5 mg tablets

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Hormone receptor-positive, her2-negative advanced/metastatic breast cancer

    phase 3 small molecule active

    1 trial

  19. Anti-PD-1 antibody drug named Serplulimab

    China SXT Pharmaceuticals

    Locally Advanced Rectal Cancer (LARC)

    phase 3 small molecule active

    1 trial

  20. Avastin 25 mg/ml concentrate for solution for infusion., MK-1084, CALCIUM LEVOFOLINATE , MK-1084, CETUXIMAB , MVASI 25 mg/mL concentrate for solution for infusion, FLUOROURACIL , Avastin 25 mg/ml concentrate for solution for infusion., MK-1084, CALCIUM FOLINATE , OXALIPLATIN , MK-1084, MVASI 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  21. Avtozma 20 mg/mL concentrate for solution for infusion., BI 764532, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Etoposid Hikma 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Boehringer Ingelheim International GmbH

    advanced or metastatic extrapulmonary neuroendocrine carcinoma

    phase 3 small molecule active

    1 trial

  22. BGJ398

    BridgeBio Oncology Therapeutics

    Advanced Cholangiocarcinoma

    phase 3 small molecule terminated

    1 trial

  23. BI 907828, BI 907828, Doxorubicin-Ebewe, 2 mg/ml, koncentrat do sporządzania roztworu do infuzji, BI 907828

    Boehringer Ingelheim International GmbH

    Advanced dedifferentiated liposarcoma

    phase 3 small molecule active

    1 trial

  24. Belzutifan, CABOZANTINIB , Lenvatinib, Lenvatinib

    Merck Sharp and Dohme

    Advanced RCC with clear cell component

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources